Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8430329 | 0.93 | HDAC1 (0.46) | ACEHDAC1HDAC6CTSBMME | |
| SCHEMBL8254276 | 0.88 | HDAC1 (0.46) | ACEHDAC1HDAC6MMEHDAC8 | |
| SCHEMBL5869899 | 0.88 | HDAC1 (0.46) | ACEHDAC1HDAC6MMEHDAC8 | |
| SCHEMBL8430008 | 0.87 | ACE2 (0.42) | ACEHDAC1HDAC6 | |
| SCHEMBL8430716 | 0.85 | MAPK1 (0.43) | ACEHDAC1HDAC6HDAC8 | |
| SCHEMBL8430327 | 0.81 | MEN1 (0.34) | ACEHDAC1HDAC6 | |
| SCHEMBL8255027 | 0.81 | HDAC1 (0.50) | HDAC1HDAC6MMEHDAC8LTA4H | |
| SCHEMBL8249245 | 0.81 | HDAC1 (0.50) | HDAC1HDAC6MMEHDAC8LTA4H | |
| SCHEMBL5870055 | 0.81 | HDAC1 (0.50) | HDAC1HDAC6MMEHDAC8LTA4H | |
| SCHEMBL8430334 | 0.80 | ACE2 (0.41) | ACEHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | ACE 1/4885HDAC1 236/4885HDAC6 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.